Oncology Drug Efficacy Evaluation Platform
Next generation therapies, including targeted anti-tumor therapies, immunotherapy, and gene therapy, have demonstrated remarkable success in treating malignant tumors and hold substantial promise for clinical translation. At the forefront of oncology research, these modalities rely on preclinical models that accurately recapitulate human-relevant tumor microenvironment and disease progression. Such models are pivotal for enhancing the precision of drug candidate screening and therapeutic efficacy assessment, key differentiators in the competitive drug discovery arena.
SMOC has established a comprehensive and professional anti-tumor efficacy evaluation platform, supported by hundreds of validated tumor models. This platform provides clients with preclinical services, including drug candidate screening, pharmacodynamic and efficacy studies, pharmacokinetic (PK) analysis, and preliminary toxicology assessment, all designed to accelerate the development of innovative cancer therapies.
